eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed indications for presbyopia, myopia progression and mydriasis.

Presentation & Investor Materials

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News Releases
02/13/24
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
01/16/24
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada
11/13/23
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
Upcoming Events
There are currently no events scheduled.